Rachid Baz, MD

Where You Are:
Rachid Baz, MD

Associate Member

Office  (888) 860-2778

Education And Training
  • Fellow, Cleveland Clinic Foundation, 2007 - Hematology and Medical Oncology
  • Resident, Cleveland Clinic Foundation, 2004 - Internal Medicine
  • MD, American University of Beirut, 2000

Dr. Baz’s research focuses on malignant hematology and involves the development and implementation of biomarker-driven therapeutics into patient-based phase I and II clinical trials, including early-phase clinical trials in multiple myeloma. In this context, he and his colleagues initiated a clinical trial of a response-adapted therapy in newly diagnosed myeloma patients who are not candidates for high-dose therapy and do not have high-risk disease. He and his team are evaluating several novel agents (novel proteasome inhibitors, novel immunomodulators as well as monoclonal antibodies). Moreover, Dr. Baz has collaborated with outcome researchers (focusing on outcomes to therapy as well as defining optimal sequences of therapy) and with basic scientists (focusing on translational research and new drug development in myeloma)

  • Hassoun Y, Kharfan-Dabaja MA, Baz R. Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response. Hematol Oncol Stem Cell Ther. 2015 Feb. Pubmedid: 25732670.
  • Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. Eur J Haematol. 2015 Jan. Pubmedid: 25600676.
  • Remily-Wood ER, Benson K, Baz RC, Chen YA, Hussein M, Hartley-Brown MA, Sprung RW, Perez B, Liu RZ, Yoder S, Teer J, Eschrich SA, Koomen JM. Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients. Proteom Clin Appl. 2014 Oct;8(9-10):783-795. Pubmedid: 24723328. Pmcid: PMC4302417.
  • Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug;124(7):1038-1046. Pubmedid: 24920586.
  • Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 Aug;27:62-73. Pubmedid: 24631834. Pmcid: PMC4108511.
  • Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson K. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar;123(12):1826-1832. Pubmedid: 24421329. Pmcid: PMC3962162.
  • Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS. A preclinical assay for chemosensitivity in multiple myeloma. Cancer Res. 2014 Jan;74(1):56-67. Pubmedid: 24310398. Pmcid: PMC3915502.
  • Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Finleyoliver E, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. Am J Hematol. 2014 Jan;89(1):62-67. Pubmedid: 24030918.
  • Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leuk Res. 2013 Sep;37(9):1077-1082. Pubmedid: 23809054.
  • Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2013 Sep;48(9):1179-1184. Pubmedid: 23542223.
  • Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar;121(11):1961-1967. Pubmedid: 23243282. Pmcid: PMC4123324.
  • Nishihori T, Abu Kar SM, Baz R, Alsina M, Harousseau JL, Kharfan-Dabaja MA. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Feb;19(8):1144-1151. Pubmedid: 23416092.
  • Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res. 2012 Nov;18(22):6155-6168. Pubmedid: 22988056. Pmcid: PMC3500436.
  • Jacobsen PB, Wells KJ, Meade CD, Quinn GP, Lee JH, Fulp WJ, Gray JE, Baz RC, Springett GM, Levine RM, Markham MJ, Schreiber FJ, Cartwright TH, Burke JM, Siegel RD, Malafa MP, Sullivan D. Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol. 2012 Jul;30(20):2516-2521. Pubmedid: 22614993.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun;157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
  • Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-511. Pubmedid: 21813352.
  • Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec;35(12):1571-1577. Pubmedid: 21752466.
  • Chen F, Pisklakova A, Li M, Baz R, Sullivan DM, Nefedova Y. Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma. Cell Oncol (Dordr). 2011 Dec;34(6):545-551. Pubmedid: 21965140. Pmcid: PMC3417352.
  • Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype. Mol Cancer Ther. 2011 Dec;10(12):2257-2266. Pubmedid: 21980133. Pmcid: PMC3237739.
  • Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010 Nov;24 Suppl 1:S13-S19. Pubmedid: 21126632.
  • Baz R, Patel M, Finley-Oliver E, Lebovic D, Hussein MA, Miller KC, Wood M, Sher T, Lee K, Chanan-Khan AA. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma. 2010 Jun;51(6):1015-1019. Pubmedid: 20367570. Pmcid: PMC4046695.
  • Hartley-Brown MA, Sullivan DM, Baz R. State-of-the-Art Management of Complications of Myeloma and Its Treatment. Adv Hematol. 2010 Jun;2010:343089. Pubmedid: 20671999.
  • Hartley MA, Tao J, Baz R. Merkel cell carcinoma in the peripheral blood of a patient with concomitant chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol. 2010 Mar;28(7):e113-e114. Pubmedid: 20008639.
  • Khoriaty R, Hussein MA, Faiman B, Kelly M, Kalaycio M, Baz R. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):E10-E13. Pubmedid: 20223721.
  • Mourad AR, Kharfan-Dabaja MA, Benson K, Moscinski LC, Baz RC. Leptomeningeal myeloma as the sole manifestation of relapse: an unusual presentation. Am J Med Sci. 2010 Jan;339(1):81-82. Pubmedid: 19875952.
  • Kelley TW, Baz R, Hussein M, Karafa M, Cook JR. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen. Hum Pathol. 2009 Mar;40(3):405-412. Pubmedid: 19070887.
  • Advani AS, Rodriguez C, Jin T, Jawde RA, Saber W, Baz R, Kalaycio M, SobecksR, Sekeres M, Tripp B, Hsi E. Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leuk Res. 2008 Jun;32(6):913-918. Pubmedid: 17928050.
  • Rodriguez C, Baz R, Jawde R, Rybicki L, Kalaycio M, Advani A, Sobecks R, Sekeres M. Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia. Leuk Res. 2008 Mar;32(3):413-420. Pubmedid: 17727945.
  • Choueiri T, Baz R, McFadden C, Khasawneh M, Karam M, Kelly M, Hussein M. An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. Bju Int. 2008 Mar;101(6):712-715. Pubmedid: 17970789.
  • Baz R, Fanning S, Kunkel L, Gaballa S, Karam MA, Reed J, Kelly M, Hussein M. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leuk Lymphoma. 2007 Dec;48(12):2338-2344. Pubmedid: 18067008.
  • Baz R, Rodriguez C, Fu A, Jawde R, Kalaycio M, Advani A, Sobecks R, SekeresMA. Impact of remission induction chemotherapy on survival in older adults with acutemyeloid leukemia. Cancer. 2007 Oct;110(8):1752-1759. Pubmedid: 17724726.
  • Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest. 2007 Oct;117(10):3107-3117. Pubmedid: 17823654. Pmcid: PMC1964509.
  • Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007 Aug;110(3):543-550. Pubmedid: 17577222.
  • Choueiri T, Rini B, Garcia J, Baz R, Abou-Jawde R, Thakkar S, Elson P, Mekhail T, Zhou M, Bukowski R. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol. 2007 Feb;18(2):249-255. Pubmedid: 17060490.
  • Baz R, Walker E, Choueiri T, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein M. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol. 2007;117(3):162-167. Pubmedid: 17148935.
  • Choueiri T, Dreicer R, Rini B, Elson P, Garcia J, Thakkar S, Baz R, Mekhail T, Jinks H, Bukowski R. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer. 2006 Dec;107(11):2609-2616. Pubmedid: 17075879.
  • Baz R, Walker E, Karam M, Choueiri T, Jawde R, Bruening K, Reed J, FaimanB, Ellis Y, Brand C, Srkalovic G, Andresen S, Knight R, Zeldis J, Hussein M. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006 Dec;17(12):1766-1771. Pubmedid: 16980599.
  • Abou-Jawde R, Baz R, Walker E, Choueiri T, Karam M, Reed J, Faiman B, Hussein M. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica. 2006 Oct;91(10):1410-1413. Pubmedid: 16963396.
  • Baz R, Hussein M. Does low-dose aspirin have antineoplastic effects in multiple myeloma?. Brit J Haematol. 2006 Aug;134(3):349-350. Pubmedid: 16848779.
  • Hussein M, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E, Andresen S, Karam M, Reed J, Faiman B, Kelly M, Walker E. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc. 2006 Jul;81(7):889-895. Pubmedid: 16835968.
  • Abou-Jawde R, Reed J, Kelly M, Walker E, Andresen S, Baz R, Karam M, Hussein M. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol. 2006;23(2):263-272. Pubmedid: 16720927.
  • Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, Karam M, Faiman B, Jawde R, Andresen S, Zeldis J, Hussein M. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005 Dec;80(12):1568-1574. Pubmedid: 16342649.
  • Baz R, Alemany C, Green R, Hussein M. Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer. 2004 Aug;101(4):790-795. Pubmedid: 15305411.
  • Holkova B, Kmieciak M, Perkins EB, Bose P, Baz R, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson JL, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala HM, Hogan K, Colevas AD, Doyle A, Figg WD, Coppola D, Roberts JD, Sullivan DM, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov;20(22):5652-5662. Pubmedid: 25248382. Pmcid: PMC4233160.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions